• Oxford-based OxSonics Therapeutics announced that the first patient was dosed in a clinical trial evaluating their SonoTran platform for treating colorectal cancer that has spread to the liver.
  • The SonoTran platform is designed to actively pump unmodified oncology drugs at the site of solid tumours to enhance their effectiveness.
  • Nearly 50 patients with liver metastases will be enrolled at Oxford University Hospitals.

  • Joe Rice will help develop and maintain comprehensive media production capabilities for the Foundation
  • He will also assist with video creation, photography, graphic design, digital marketing, and media outreach.

  • For more than a decade, Howard Eisenberg, MD, has been a cornerstone of the focused ultrasound program at the University of Maryland.
  • His work is primarily treating movement disorders – like essential tremor and Parkinson’s disease – and pain.
  • The Maryland team offers focused ultrasound both in clinical trials and commercial treatments.

  • OxSonics Therapeutics is a clinical-stage oncology company that has developed an ultrasound-based drug delivery platform.
  • Their SonoTran Platform uses low-intensity focused ultrasound combined with injectable ‘SonoTran Particles’ to enhance the dose and penetration of unmodified cancer drugs into solid tumors to enable more effective therapies for cancer patients.

The Focused Ultrasound Foundation Newsletter

Our newsletter delivers updates for clinicians, researchers and patients. Sign up and stay on top of the rapid advancements of this innovative medical technology.

Sign Up  Read the Latest Issue

Read The Tumor  by John Grisham

From John Grisham, comes a story where today’s medical fiction could become tomorrow’s lifesaving reality.

Download a Free eBook or Audiobook

Contact Details

Call Us
Find Us
Focused Ultrasound Foundation
1230 Cedars Court, Suite 206 Charlottesville, VA 22903
Whitelist Instructions